Skip to Main content Skip to Navigation
Journal articles

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Abstract : A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were randomized in double-blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. The volunteers then underwent a structured treatment interruption between M5 and M7.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-01466152
Contributor : Françoise Dignat-George <>
Submitted on : Monday, February 13, 2017 - 1:51:25 PM
Last modification on : Friday, January 24, 2020 - 7:06:02 PM

Identifiers

  • HAL Id : hal-01466152, version 1
  • PUBMED : 27036656

Collections

Citation

Erwann P Loret, Albert Darque, Elisabeth Jouve, Elvenn A Loret, Corinne Nicolino-Brunet, et al.. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology, BioMed Central, 2016, pp.21. ⟨hal-01466152⟩

Share

Metrics

Record views

184